TABLE 1.
Resolved susceptibility test results for clinical isolates of MTBC by method of proportion, BACTEC TB 460, and ESP II
| Drug and result | No. of isolates with result bya:
|
|||
|---|---|---|---|---|
| MOP | BACTEC | ESP II
|
||
| McFarland-equivalent inoculum | Seed inoculum | |||
| Isoniazid (lowb) | ||||
| Susceptible | 16 | 16 | 18 | 18 |
| Resistant | 4 | 4 | 2 | 2 |
| Isoniazid (highc) | ||||
| Susceptible | 19 | 18 | 19 | 19 |
| Resistant | 1 | 2 | 1 | 1 |
| Rifampin | ||||
| Susceptible | 17 | 17 | 17 | 17 |
| Resistant | 3 | 3 | 3 | 3 |
| Ethambutol | ||||
| Susceptible | 20 | 20 | 20 | 20 |
| Resistant | 0 | 0 | 0 | 0 |
| Streptomycin | ||||
| Susceptible | 18 | 18 | 19 | 19 |
| Resistant | 2 | 2 | 1 | 1 |
a
MOP, method of proportion; BACTEC, BACTEC TB 460.
b
Low, 0.2 μg/ml for method of proportion and 0.1 μg/ml for BACTEC TB 460 and ESP II.
c
High, 1.0 μg/ml for method of proportion and 0.4 μg/ml for BACTEC TB 460 and ESP II.